Adaptive Biotech Teams Up With NeoGenomics To Advance MRD Monitoring Options

(RTTNews) - Adaptive Biotechnologies Corp. (ADPT), Tuesday announced a partnership with NeoGenomics, Inc. (NEO), an oncology testing services company, to advance minimal residual disease or MRD monitoring options in patients with certain blood cancers. Terms of the deal have not been disclosed.

Under the collaboration, Adaptive's next-generation sequencing-based clonoSEQ will be integrated with NeoGenomics' comprehensive and customized assessment services for complex blood cancers - COMPASS and CHART. This will help evaluate patient's risk status, showing real-time disease progress, and providing personalized treatment strategies.

In the pre-market hours, Adaptive's stock is trading at $6.52, up 0.94 percent, and NeoGenomics is trading at $12.78, up 2.71 percent on the Nasdaq.